MDCX — Medicus Pharma Share News
0.000.00%
Last trade - 00:00NASDAQ TRADE HALT CONTINUES HALT NEWS PENDING AT 03:28 AM
NASDAQ TRADE HALT CONTINUES HALT NEWS PENDING AT 03:28 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:50 PM
Brief: Medicus Pharma Submits Optimized Teverelix® Registrational Protocol To FDA To Create Partner Ready Program In Advanced Prostate Cancer
Brief: Medicus Pharma Advances Transformation Into A Precision Oncology-Led Biotechnology Company
U.S. STOCKS ON THE MOVE-Principal Financial Group, NetApp
U.S. STOCKS ON THE MOVE-Genesco, Fervo Energy, Tyson Foods
U.S. STOCKS ON THE MOVE-Gold miners, Polestar Automotive, Nvidia
Medicus Pharma surges on Pfizer licensing deal for experimental cancer therapy
Medicus Pharma Ltd reports results for the quarter ended June 30 - Earnings Summary
Medicus Pharma Q2 net loss widens as operating expenses rise
Medicus Pharma Ltd expected to post a loss of 13 cents a share - Earnings Preview
Brief: Medicus Pharma - Uae Department Of Health Grants Ind Authorization For Precision-E2 Phase 2A Study Of Teverelix
Brief: Medicus Pharma Receives FDA “Study May Proceed” Letter For NDA-Enabling Registrational Skinject® Study In Patients With Gorlin Syndrome
Brief: Medicus Pharma Ltd May Offer And Sell Common Shares Up To $50 Million Aggregate Through Agents
Brief: Medicus Pharma Ltd Clarifies Positive Skinject Phase 2 Dataset
Brief: Medicus Pharma Reports Kol Validation Of Skinject Phase 2 Data Of 80% Overall Response Rate
Brief: Medicus Pharma Announces Skinject® Phase 2 Principal Investigator And Key Opinion Leader (Kol), Babar K. Rao MD, Faad, To Provide Clinical Interpretation Of Positive Data During Business Update Webcast On March 26
U.S. STOCKS ON THE MOVE-Tesla, JPMorgan, Intel